Sotrovimab: Neutralizing Antibody to Combat COVID-19
The University of Louisville Journal of Respiratory Infections · 20.04.2022 · 6 (1)
DOI: 10.55504/2473-2869.1240 ↗Kurz gefasst
Fachartikel in der Zeitschrift The University of Louisville Journal of Respiratory Infections, online erschienen am 20.04.2022. Verfasst von Aya Allam und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sotrovimab is a new therapeutic agent to attenuate COVID-19. It is considered a welcome pharmaceutical preparation in light of SARS-CoV-2 variants, such as Omicron. Some other monoclonal antibody medications have low effectiveness at blocking Omicron’s SARS-CoV-2 cell access. Sotrovimab fills an important therapeutic niche for victims of Omicron infection and is indicated for anyone with medical contraindications to vaccines, persons with serious comorbidities, and immunocompromised persons with suboptimal response to vaccines, and it may be especially helpful with the emergence of variant viral infections that evade vaccineor illness-derived immunity.[1, 2] Sotrovimab reduces the risk of disease progression among high-risk patients with mild-tomoderate COVID-19.[3] Sotrovimab may also reduce the percentage of patients who require oxygen.[4] It seems that sotrovimab is a better choice for dealing with severe or non-severe COVID-19 patients.[5] Hopefully, it will provide high efficacy to patients with early COVID-19, minimizing hospitalizations, morbidity, mortality, and/or healthcare system overload.
Zitieren
APA
Allam, A., & Lippmann, S. (2022). Sotrovimab: Neutralizing Antibody to Combat COVID-19. The University of Louisville Journal of Respiratory Infections, 6(1). https://doi.org/10.55504/2473-2869.1240
Vancouver
Allam A, Lippmann S. Sotrovimab: Neutralizing Antibody to Combat COVID-19. The University of Louisville Journal of Respiratory Infections. 2022;6(1). doi:10.55504/2473-2869.1240
BibTeX
@article{Allam2022,
author = {Allam, Aya and Lippmann, Steven},
title = {Sotrovimab: Neutralizing Antibody to Combat COVID-19},
journal = {The University of Louisville Journal of Respiratory Infections},
year = {2022},
volume = {6},
number = {1},
doi = {10.55504/2473-2869.1240}
}
EUVIMED